Source:

Press Release

November 28, 2021
1 min read
Save

NuVasive reports decreased net sales due to COVID-19, health care staffing shortages

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NuVasive Inc. announced decreased net sales due to the COVID-19 pandemic, health care staffing shortages and limited availability of specialized products, according to its third-quarter 2021 financial report.

NuVasive reported $270.8 million in total net sales in the third quarter of 2021, an 8.3% decrease compared with the $295.3 million in total net sales during the prior year period. The company also reported a generally accepted accounting principles (GAAP) operating margin of 2.4% and a GAAP diluted loss per share of $0.42, according to the release.

“The third quarter presented unexpected challenges for elective surgical procedures due to the negative impact from the resurgence of COVID-19 and health care staffing shortages,” J. Christopher Barry, CEO of NuVasive, said in the release. “Despite these external factors, our strategy remains unchanged. The company is well-positioned with multiple vectors of growth to create increased value for our stakeholders in 2022 and beyond. With the recent pulse commercial launch and continued adoption of our C360 portfolio – highlighted by the simplify cervical disc – I am confident in our ability to further transform surgery, advance care, and change patient lives around the world,” Barry added.